Electroacupuncture Alleviates KOA-Induced Pain and Cartilage Degeneration via NGF/TrkA Pathway.

Knee osteoarthritis causes chronic pain and cartilage breakdown that limits mobility, but current treatments often fall short or cause unwanted side effects. Researchers investigated whether electroacupuncture—a form of acupuncture using mild electrical stimulation—could help, and if so, how it works at the molecular level. In this animal study, rats with induced knee osteoarthritis received electroacupuncture at two specific points near the knee: ST35 (Dubi) and EX-LE5 (Neixiyan). The researchers measured pain responses, weight-bearing patterns, cartilage health, and examined tissue samples to understand the biological mechanisms. The results were impressive: electroacupuncture significantly reduced pain sensitivity, improved weight distribution on the affected leg, decreased spontaneous pain behaviors, and protected cartilage from further degeneration. The study identified that electroacupuncture works by blocking a specific pain pathway called NGF/TrkA, which is overactive in osteoarthritis. This pathway involves nerve growth factor (NGF) and its receptor (TrkA) that amplify pain signals. Electroacupuncture reduced the activity of this pathway in both the knee joint and in specific pain-sensing nerve cells, particularly those containing a substance called CGRP. The treatment also lowered inflammatory chemicals and cartilage-degrading enzymes. While this research was conducted in animals and human studies are needed, it provides scientific evidence for how electroacupuncture may relieve knee osteoarthritis pain and slow cartilage damage. If you're considering acupuncture for knee osteoarthritis, seek treatment from a licensed acupuncturist trained in electroacupuncture techniques.

This preclinical study investigated electroacupuncture's mechanisms in monosodium iodoacetate-induced knee osteoarthritis in rats. EA was administered at ST35 and EX-LE5 acupoints. Outcomes assessed included mechanical allodynia (von Frey testing), weight-bearing asymmetry, spontaneous pain, cartilage degeneration (toluidine blue staining), and protein expression via immunofluorescence. EA significantly reduced mechanical allodynia (p<0.001), weight-bearing asymmetry (p<0.001), and spontaneous pain (p<0.001). Chondroprotective effects included decreased macroscopic chondropathy scores (p<0.01) and cartilage degeneration scores (p<0.001), with inhibited MMP13 expression (p<0.05). Mechanistically, EA suppressed NGF (p<0.001) and TrkA (p<0.05) expression in joint tissues, decreased PGP9.5 overexpression (p<0.05), and downregulated IL-1β (p<0.01) and TNF-α (p<0.01). Pharmacological manipulation confirmed NGF/TrkA pathway involvement. Notably, EA selectively downregulated TrkA in CGRP+ DRG neurons (p<0.01) but not IB4+ or NF200+ subtypes. Clinical relevance: EA demonstrates both analgesic and disease-modifying potential in KOA through NGF/TrkA pathway modulation, particularly affecting peptidergic nociceptors.